181 related articles for article (PubMed ID: 23888610)
1. Efficacy of the biocide Steri-7 against the common Gram-negative bacterial pathogens (Burkholderia cenocepacia, Burkholderia gladioli, Burkholderia multivorans, Pseudomonas aeruginosa and Stenotrophomonas maltophilia) associated with cystic fibrosis (CF).
Moore JE; Rao JR
Br J Biomed Sci; 2013; 70(2):80-1. PubMed ID: 23888610
[No Abstract] [Full Text] [Related]
2. Belfast Agar-a simple laboratory medium to separate Pseudomonas aeruginosa from pan-resistant Burkholderia cenocepacia isolated from the sputum of patients with cystic fibrosis (CF).
Caskey S; Moore JE; McCaughan J; Rendall JC
Br J Biomed Sci; 2018 Apr; 75(2):101-103. PubMed ID: 29513134
[No Abstract] [Full Text] [Related]
3. Inhibition of co-colonizing cystic fibrosis-associated pathogens by Pseudomonas aeruginosa and Burkholderia multivorans.
Costello A; Reen FJ; O'Gara F; Callaghan M; McClean S
Microbiology (Reading); 2014 Jul; 160(Pt 7):1474-1487. PubMed ID: 24790091
[TBL] [Abstract][Full Text] [Related]
4. Bacterial cis-2-unsaturated fatty acids found in the cystic fibrosis airway modulate virulence and persistence of Pseudomonas aeruginosa.
Twomey KB; O'Connell OJ; McCarthy Y; Dow JM; O'Toole GA; Plant BJ; Ryan RP
ISME J; 2012 May; 6(5):939-50. PubMed ID: 22134647
[TBL] [Abstract][Full Text] [Related]
5. In vitro antimicrobial activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and other non-fermenting Gram-negative bacteria in adults with cystic fibrosis.
Gramegna A; Millar BC; Blasi F; Elborn JS; Downey DG; Moore JE
J Glob Antimicrob Resist; 2018 Sep; 14():224-227. PubMed ID: 29559421
[TBL] [Abstract][Full Text] [Related]
6. Denitrification by cystic fibrosis pathogens - Stenotrophomonas maltophilia is dormant in sputum.
Kolpen M; Kragh KN; Bjarnsholt T; Line L; Hansen CR; Dalbøge CS; Hansen N; Kühl M; Høiby N; Jensen PØ
Int J Med Microbiol; 2015 Jan; 305(1):1-10. PubMed ID: 25441256
[TBL] [Abstract][Full Text] [Related]
7. Activation of MMP-9 by human lung epithelial cells in response to the cystic fibrosis-associated pathogen Burkholderia cenocepacia reduced wound healing in vitro.
Wright C; Pilkington R; Callaghan M; McClean S
Am J Physiol Lung Cell Mol Physiol; 2011 Oct; 301(4):L575-86. PubMed ID: 21743026
[TBL] [Abstract][Full Text] [Related]
8. Clinafloxacin for Treatment of Burkholderia cenocepacia Infection in a Cystic Fibrosis Patient.
Balwan A; Nicolau DP; Wungwattana M; Zuckerman JB; Waters V
Antimicrob Agents Chemother; 2016 Jan; 60(1):1-5. PubMed ID: 26722110
[TBL] [Abstract][Full Text] [Related]
9. Pseudomonas aeruginosa and Burkholderia cenocepacia infections in patients affected by cystic fibrosis: serum resistance and antibody response.
Savoia D; Deplano C; Zucca M
Immunol Invest; 2008; 37(1):19-27. PubMed ID: 18214797
[TBL] [Abstract][Full Text] [Related]
10. Synthetic cystic fibrosis sputum medium diminishes Burkholderia cenocepacia antifungal activity against Aspergillus fumigatus independently of phenylacetic acid production.
Lightly TJ; Phung RR; Sorensen JL; Cardona ST
Can J Microbiol; 2017 May; 63(5):427-438. PubMed ID: 28178425
[TBL] [Abstract][Full Text] [Related]
11. Bacterial contaminants in cosmetic products from a patient with cystic fibrosis.
O'Gorman K; Xu J; Elborn JS; Boyle L; Millar BC; Goldsmith CE; Moore JE
Br J Biomed Sci; 2006; 63(3):141-2. PubMed ID: 17058716
[No Abstract] [Full Text] [Related]
12. Localization of Burkholderia cepacia complex bacteria in cystic fibrosis lungs and interactions with Pseudomonas aeruginosa in hypoxic mucus.
Schwab U; Abdullah LH; Perlmutt OS; Albert D; Davis CW; Arnold RR; Yankaskas JR; Gilligan P; Neubauer H; Randell SH; Boucher RC
Infect Immun; 2014 Nov; 82(11):4729-45. PubMed ID: 25156735
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in cross-infection in cystic fibrosis: Burkholderia cepacia complex, Pseudomonas aeruginosa, MRSA and Pandoraea spp.
Jones AM; Webb AK
J R Soc Med; 2003; 96 Suppl 43(Suppl 43):66-72. PubMed ID: 12906328
[No Abstract] [Full Text] [Related]
14. Pseudomonas aeruginosa displays an altered phenotype in vitro when grown in the presence of mannitol.
Moore JE; Rendall JC; Downey DG
Br J Biomed Sci; 2015; 72(3):115-9. PubMed ID: 26510267
[TBL] [Abstract][Full Text] [Related]
15. Burkholderia species infections in patients with cystic fibrosis in British Columbia, Canada. 30 years' experience.
Zlosnik JE; Zhou G; Brant R; Henry DA; Hird TJ; Mahenthiralingam E; Chilvers MA; Wilcox P; Speert DP
Ann Am Thorac Soc; 2015 Jan; 12(1):70-8. PubMed ID: 25474359
[TBL] [Abstract][Full Text] [Related]
16. In vitro efficacy of high-dose tobramycin against Burkholderia cepacia complex and Stenotrophomonas maltophilia isolates from cystic fibrosis patients.
Ratjen A; Yau Y; Wettlaufer J; Matukas L; Zlosnik JE; Speert DP; LiPuma JJ; Tullis E; Waters V
Antimicrob Agents Chemother; 2015 Jan; 59(1):711-3. PubMed ID: 25348526
[TBL] [Abstract][Full Text] [Related]
17. Cystic fibrosis pathogens survive for extended periods within cough-generated droplet nuclei.
Wood ME; Stockwell RE; Johnson GR; Ramsay KA; Sherrard LJ; Kidd TJ; Cheney J; Ballard EL; O'Rourke P; Jabbour N; Wainwright CE; Knibbs LD; Sly PD; Morawska L; Bell SC
Thorax; 2019 Jan; 74(1):87-90. PubMed ID: 29627800
[TBL] [Abstract][Full Text] [Related]
18. Major Aspects of Burkholderia gladioli and Burkholderia cepacia Infections in Children.
Bedir Demirdag T; Ozkaya Parlakay A; Aygar IS; Gulhan B; Kanik Yuksek S
Pediatr Infect Dis J; 2020 May; 39(5):374-378. PubMed ID: 32118858
[TBL] [Abstract][Full Text] [Related]
19. In vitro interactions of tobramycin with various nonantibiotics against Pseudomonas aeruginosa and Burkholderia cenocepacia.
Treerat P; Widmer F; Middleton PG; Iredell J; George AM
FEMS Microbiol Lett; 2008 Aug; 285(1):40-50. PubMed ID: 18513356
[TBL] [Abstract][Full Text] [Related]
20. [Pathogenic bacteria in cystic fibrosis].
Mariani-Kurkdjian P; Bingen E
Arch Pediatr; 2003 Sep; 10 Suppl 2():342s-346s. PubMed ID: 14671932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
